Overview

STATEMENT OF NEED

Precision medicine is a cutting-edge approach that incorporates an individual’s genomic, environmental, and lifestyle information to deliver personalized healthcare. Genetic testing and counseling are crucial components of precision medicine, enabling clinicians to deliver the right care to the right patient at the right time (Turbitt et al, 2023). However, genetic testing often remains an untapped resource for patients who may benefit from genetic risk assessment and cancer surveillance, and barriers at the patient, provider, and systems level may impede its integration into the clinic (Dusic et al, 2022). In this webinar, Dr. Filipa Lynce, Director of the Inflammatory Breast Center at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School, and Catherine Skefos, Certified Genetic Counselor in the Clinical Cancer Genetics Program at the University of Texas MD Anderson Cancer Center, will explore solutions for overcoming barriers to genetic testing referral, clinical trial data and real-world evidence for targeted therapies for BRCA-mutated solid tumors, and strategies for effectively counseling patients regarding complex genetic information.

Learning Objectives

Upon completion of this activity, participants should be able to

• Explain the rationale behind referring patients for genetic risk assessment and testing and selecting the appropriate testing methodology 
• Identifying potential solutions to common barriers to genetic testing referral and integration into clinical practice 
• Evaluate existing and novel targeted therapies for BRCA-mutated solid tumors based on key clinical trial data and real-world evidence 
• Apply expert strategies to clearly communicate complex genetic information, counseling process, and referral pathways to patients and family members

Target Audience

Primary care providers (PCPs), medical oncologists, medical geneticists, genetic counselors, oncology nurses, and advanced practice providers involved in referring or conducting genetic counseling and testing of patients with or at risk of cancer.

Accreditation

i3 Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For more information please visit the official event page.